Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vemurafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 2/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891936 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29356185 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29355460 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL17784481 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298368 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL19575141 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298927 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7876722 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20408711 | 0.94 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL293053 | 0.93 | CYP2C19 (1.00) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16922 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146289-A1 | ASSESSING AND TREATING MELANOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20130078252-A1 | COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | claimed |
| WO-2013043715-A1 | COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS | GENENTECH, INC. (US) | 2013-03-28 | — | — | WO | claimed |
| US-20120258461-A1 | METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT | THE UNITED STATES OF AMERICA AS REPRESENTED BY | 2012-10-11 | — | — | US | claimed |
| US-20120148533-A1 | COMBINATION THERAPY | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | claimed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | claimed |
| US-20120045433-A1 | COMBINATION THERAPY | DHINGRA KAPIL (US) | 2012-02-23 | — | — | US | claimed |
| US-20120045434-A1 | COMBINATION THERAPY | HOFFMANN-LA ROCHE INC. | 2012-02-23 | — | — | US | claimed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | claimed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | claimed |